A Randomized, Controlled Trial to Investigate the Effect of Ciclesonide and Beclomethasone Dipropionate on Eye Lens Opacity

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2007, Available from: www.ginasthma.org
   Google Scholar
• National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Programme, Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Accessed July 2008
   Google Scholar
• Allen D B. Inhaled steroids for children: effects on growth, bone, and adrenal function. Endocrinol Metab Clin North Am 2005; 34: 555–64; viii
   PubMedGoogle Scholar
• Allen D B, Bielory L, Derendorf H, Dluhy R, Colice G L, Szefler S J. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112: S1–40
   PubMedGoogle Scholar
• Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100: 1307–1317
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941–955
   PubMed Web of Science ®Google Scholar
• Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–1174
   PubMed Web of Science ®Google Scholar
• Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children. Compr Ophthalmol Update 2006; 7: 31–39
   PubMedGoogle Scholar
• Uboweja A, Malhotra S, Pandhi P. Effect of inhaled corticosteroids on risk of development of cataract: a meta-analysis. Fundam Clin Pharmacol 2006; 20: 305–309
   PubMed Web of Science ®Google Scholar
• Chylack L T, Jr., Wolfe J K, Singer D M, Leske M C, Bullimore M A, Bailey I L, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993; 111: 831–836
   PubMed Web of Science ®Google Scholar
• Karbassi M, Khu P M, Singer D M, Chylack L T, Jr. Evaluation of lens opacities classification system III applied at the slitlamp. Optom Vis Sci 1993; 70: 923–928
   PubMed Web of Science ®Google Scholar
• Bailey I L, Lovie J E. The design and use of a new near-vision chart. Am J Optom Physiol Opt 1980; 57: 378–387
   PubMedGoogle Scholar
• Ottar W L. Tonometry. Insight 1998; 23: 11–17
   PubMedGoogle Scholar
• Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107–1136
   PubMed Web of Science ®Google Scholar
• Nayak A, Nathan R, Williams J, Kundu S, Lloyd M, Banerji D. Ciclesonide does not suppress the hypothalamic-pituitary-adrenal axis function in patients with severe persistent asthma: results of a long-term study. Ann Allergy Asthma Immunol 2005; 94: 170, (Abstract P64)
   Google Scholar
• Leske M C, Chylack L T, Jr., Wu S Y, Schoenfeld E, He Q, Friend J, et al. Incidence and progression of nuclear opacities in the Longitudinal Study of Cataract. Ophthalmology 1996; 103: 705–712
   PubMed Web of Science ®Google Scholar
• Leske M C, Chylack L T, Jr., He Q, Wu S Y, Schoenfeld E, Friend J, et al. Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group. Ophthalmology 1997; 104: 1987–1993
   PubMedGoogle Scholar
• Leske M C, Chylack L T, Jr., He Q, Wu S Y, Schoenfeld E, Friend J, et al. Risk factors for nuclear opalescence in a longitudinal study. LSC Group. Longitudinal Study of Cataract. Am J Epidemiol 1998; 147: 36–41
   PubMedGoogle Scholar
• Srinivasan M, Rahmathullah R, Blair C R, Murphy A C, Beck R W, Wilkins J H, et al. Cataract progression in India. Br J Ophthalmol 1997; 81: 896–900
   PubMed Web of Science ®Google Scholar
• Leach C L, Davidson P J, Hasselquist B E, Boudreau R J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. Chest 2002; 122: 510–516
   PubMed Web of Science ®Google Scholar
• Leach C L, Bethke T D, Boudreau R J, Hasselquist B E, Drollmann A, Davidson P, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19: 117–126
   PubMedGoogle Scholar
• Davies R J, Stampone P, O'Connor B J. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92(Suppl A)23–31
   PubMedGoogle Scholar
• Cumming R G, Mitchell P, Leeder S R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14
   PubMed Web of Science ®Google Scholar
• Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–543
   PubMed Web of Science ®Google Scholar
• Smeeth L, Boulis M, Hubbard R, Fletcher A E. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003; 87: 1247–1251
   PubMed Web of Science ®Google Scholar
• Leske M C, Wu S Y, Nemesure B, Hennis A. Risk factors for incident nuclear opacities. Ophthalmology 2002; 109: 1303–1308
   PubMed Web of Science ®Google Scholar
• Chylack L T, Jr. Cataracts and inhaled corticosteroids. N Engl J Med 1997; 337: 46–48
   PubMedGoogle Scholar
• Hodge W G, Whitcher J P, Satariano W. Risk factors for age-related cataracts. Epidemiol Rev 1995; 17: 336–346
   PubMed Web of Science ®Google Scholar
• Hennis A, Wu S Y, Nemesure B, Leske M C. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 2004; 122: 525–530
   PubMedGoogle Scholar
• Langdon C G, Adler M, Mehra S, Alexander M, Drollmann A. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005; 99: 1275–1285
   PubMed Web of Science ®Google Scholar
• Chapman K R, Patel P, D'Urzo A D, Alexander M, Mehra S, Oedekoven C, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60: 330–337
   PubMed Web of Science ®Google Scholar